DrugPatentWatch Database Preview

Details for Patent: 7,772,209

« Back to Dashboard

Which drugs does patent 7,772,209 protect, and when does it expire?

Patent 7,772,209 protects ALIMTA and is included in one NDA.

Protection for ALIMTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 7,772,209

Title:	Antifolate combination therapies
Abstract:	A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
Inventor(s):	Niyikiza; Clet (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	11/776,329
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,772,209
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,772,209
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 7,772,209

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-002	Sep 7, 2007		RX	Yes	Yes					Y
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-001	Feb 4, 2004		RX	Yes	Yes					Y

International Family Members for US Patent 7,772,209

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	359823
Australia	6968801
Cyprus	1107649
Germany	60127970
Denmark	1313508
European Patent Office	1313508